María-Victoria Mateos, MD, PhD, shares the results of a subset analysis of TOURMALINE-MM1, which showed that patients with prior exposure to proteasome inhibitors still benefited from ixazomib treatment.
Ixazomib Benefit Persists Despite Prior Therapy in TOURMALINE-MM1 Subset Analysis
Recent Articles
Zanubrutinib Approved for Waldenström Macroglobulinemia
The U.S. Food and Drug Administration (FDA) has approved zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia (WM).
This approval is based on...
Two Decades After 9/11, Cancer and Other Chronic Conditions Linger
The World Trade Center Health Program (WTCHP) has identified around 70 forms of cancer stemming from the September 11, 2001 terrorist attack, affecting first...
FDA Grants Orphan Drug Designation to Gavo-Cel for Cholangiocarcinoma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to T-cell therapy gavocabtagene autoleucel (gavo-cel) for the treatment of cholangiocarcinoma.
TCR2 Therapeutics, the...
Organizations Comment on the FDA’s Draft Guidance Expanding Clinical Trial Eligibility
Various medical and patient associations, a patient advocacy organization, and a drug manufacturer expressed support for the U.S. Food and Drug Administration’s (FDA’s) draft...
Democrats Consider Plan to Cover Uninsured in Non-Medicaid Expansion States
As part of a $3.5 trillion package proposal, Congressional Democrats are crafting a new federal program to provide health insurance coverage to more than...
Current Issue
September 2021 Volume 7 Issue 11
This issue discusses fertility preservation for young patients with cancer, reviews treatment options for primary immune thrombocytopenia, and more.